---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-005052"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:08:42.025775+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apellis reports $709M preliminary FY2024 U.S. net product revenue, COO Townsend to depart

## Summary
- Preliminary FY2024 U.S. net product revenues $709M; SYFOVRE $611M (120% YoY growth), EMPAVELI $98M.
- Cash and equivalents $410M as of Dec 31, 2024, up from $351M a year earlier.
- sNDA for C3G/IC-MPGN expected early 2025; 2H 2025 launch if approved. Phase 3 FSGS and DGF studies planned 2H 2025.
- COO Adam Townsend to depart Feb 21, 2025; David Acheson named EVP of commercial.
- Keli Walbert elected to Board; ex-U.S. workforce reduced by ~40 employees.

## SEC filing metadata
- accession: 0001193125-25-005052
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312525005052/0001193125-25-005052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312525005052/d885806d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-005052
- JSON: https://secwatch.observer/filing/0001193125-25-005052.json
- Plain text: https://secwatch.observer/filing/0001193125-25-005052.txt

## Key facts
- Executive change
  Adam Townsend departed as Chief Operating Officer at Apellis Pharmaceuticals, Inc..
  - Action: resign
  - Role: Chief Operating Officer
  source text: On January 10, 2025, the Company and Adam Townsend mutually agreed that Mr. Townsend will resign as the Company’s Chief Operating Officer effective as of February 21, 2025 (the “Separation Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312525005052/0001193125-25-005052-index.htm
- Executive change
  Keli Walbert was elected as Director at Apellis Pharmaceuticals, Inc..
  - Action: elected
  - Role: Director
  source text: On January 8, 2025, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Keli Walbert to the Board as a Class II director to serve until the Annual Meeting of Stockholders to be held in 2025 or until her successor has been duly elected and qualified or until her earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312525005052/0001193125-25-005052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.